NATERA, INC. Deferred Foreign Income Tax Expense (Benefit)
NATERA, INC. (NTRA) reported Deferred Foreign Income Tax Expense (Benefit) of $1.90 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2022-02-25
- NATERA, INC. deferred foreign income tax expense (benefit) for fiscal 2019 was $1.90M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2019-12-31 | $1.90M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |